199 related articles for article (PubMed ID: 37947652)
1. Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas.
Warda A; Staniszewski LJP; Sabir Z; Livingston S; Sausedo M; Reshi S; Ron E; Applegate MT; Haddad D; Khamisi M; Marshall PA; Wagner CE; Jurutka PW
Cells; 2023 Nov; 12(21):. PubMed ID: 37947652
[TBL] [Abstract][Full Text] [Related]
2. An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.
Jurutka PW; di Martino O; Reshi S; Mallick S; Sausedo MA; Moen GA; Lee IJ; Ivan DJ; Krall TD; Peoples SJ; Perez A; Tromba L; Le A; Khadka I; Petros R; Savage BM; Salama E; Salama J; Ziller JW; Noh Y; Lee MY; Liu W; Welch JS; Marshall PA; Wagner CE
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555852
[TBL] [Abstract][Full Text] [Related]
3. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB).
Jurutka PW; di Martino O; Reshi S; Mallick S; Sabir ZL; Staniszewski LJP; Warda A; Maiorella EL; Minasian A; Davidson J; Ibrahim SJ; Raban S; Haddad D; Khamisi M; Suban SL; Dawson BJ; Candia R; Ziller JW; Lee MY; Liu C; Liu W; Marshall PA; Welch JS; Wagner CE
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830251
[TBL] [Abstract][Full Text] [Related]
4. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-yl)amino)nicotinic Acid (NEt-TMN).
Heck MC; Wagner CE; Shahani PH; MacNeill M; Grozic A; Darwaiz T; Shimabuku M; Deans DG; Robinson NM; Salama SH; Ziller JW; Ma N; van der Vaart A; Marshall PA; Jurutka PW
J Med Chem; 2016 Oct; 59(19):8924-8940. PubMed ID: 27592633
[TBL] [Abstract][Full Text] [Related]
5. Modeling, synthesis and biological evaluation of potential retinoid X receptor-selective agonists: novel halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
Furmick JK; Kaneko I; Walsh AN; Yang J; Bhogal JS; Gray GM; Baso JC; Browder DO; Prentice JL; Montano LA; Huynh CC; Marcus LM; Tsosie DG; Kwon JS; Quezada A; Reyes NM; Lemming B; Saini P; van der Vaart A; Groy TL; Marshall PA; Jurutka PW; Wagner CE
ChemMedChem; 2012 Sep; 7(9):1551-66. PubMed ID: 22927238
[TBL] [Abstract][Full Text] [Related]
6. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.
Chou CF; Hsieh YH; Grubbs CJ; Atigadda VR; Mobley JA; Dummer R; Muccio DD; Eto I; Elmets CA; Garvey WT; Chang PL
J Dermatol Sci; 2018 Jun; 90(3):343-356. PubMed ID: 29599065
[TBL] [Abstract][Full Text] [Related]
7. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN.
Wagner CE; Jurutka PW
Methods Mol Biol; 2019; 2019():109-121. PubMed ID: 31359392
[TBL] [Abstract][Full Text] [Related]
8. Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
Wagner CE; Jurutka PW; Marshall PA; Groy TL; van der Vaart A; Ziller JW; Furmick JK; Graeber ME; Matro E; Miguel BV; Tran IT; Kwon J; Tedeschi JN; Moosavi S; Danishyar A; Philp JS; Khamees RO; Jackson JN; Grupe DK; Badshah SL; Hart JW
J Med Chem; 2009 Oct; 52(19):5950-66. PubMed ID: 19791803
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Zhang C; Hazarika P; Ni X; Weidner DA; Duvic M
Clin Cancer Res; 2002 May; 8(5):1234-40. PubMed ID: 12006543
[TBL] [Abstract][Full Text] [Related]
10. Methods to Assess Activity and Potency of Rexinoids Using Rapid Luciferase-Based Assays: A Case Study with NEt-TMN.
Jurutka PW; Wagner CE
Methods Mol Biol; 2019; 2019():95-108. PubMed ID: 31359391
[TBL] [Abstract][Full Text] [Related]
11. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
12. Modeling, synthesis, and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene) and (E)-3-(3-(1,2,3,4-tetrahydro-1,1,4,4,6-pentamethylnaphthalen-7-yl)-4-hydroxyphenyl)acrylic acid (CD3254).
Jurutka PW; Kaneko I; Yang J; Bhogal JS; Swierski JC; Tabacaru CR; Montano LA; Huynh CC; Jama RA; Mahelona RD; Sarnowski JT; Marcus LM; Quezada A; Lemming B; Tedesco MA; Fischer AJ; Mohamed SA; Ziller JW; Ma N; Gray GM; van der Vaart A; Marshall PA; Wagner CE
J Med Chem; 2013 Nov; 56(21):8432-54. PubMed ID: 24180745
[TBL] [Abstract][Full Text] [Related]
13. RARα/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines.
Wang L; DeMarco SS; Peaks MS; Maiorana-Boutilier AL; Chen J; Crouch MJ; Shewchuk BM; Shaikh SR; Phillips CM; Bridges LC
Exp Dermatol; 2017 Nov; 26(11):1004-1011. PubMed ID: 28370539
[TBL] [Abstract][Full Text] [Related]
14. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma.
Nieto-Rementería N; Pérez-Yarza G; Boyano MD; Apraiz A; Izu R; Díaz-Pérez JL; Asumendi A
Br J Dermatol; 2009 Mar; 160(3):519-26. PubMed ID: 19067706
[TBL] [Abstract][Full Text] [Related]
15. Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptor.
Lin JH; Kim EJ; Bansal A; Seykora J; Richardson SK; Cha XY; Zafar S; Nasta S; Wysocka M; Benoit B; Rook AH; Fakharzadeh SS
Blood; 2008 Sep; 112(6):2484-8. PubMed ID: 18559673
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.
Gorgun G; Foss F
Blood; 2002 Aug; 100(4):1399-403. PubMed ID: 12149223
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma.
Cayrol F; Revuelta MV; Debernardi M; Paulazo A; Phillip JM; Zamponi N; Sterle H; Díaz Flaqué MC; Magro C; Marullo R; Mulvey E; Ruan J; Cremaschi GA; Cerchietti L
Mol Cancer Ther; 2022 Sep; 21(9):1485-1496. PubMed ID: 35793463
[TBL] [Abstract][Full Text] [Related]
18. Activation of the retinoid X receptor modulates angiotensin II-induced smooth muscle gene expression and inflammation in vascular smooth muscle cells.
Lehman AM; Montford JR; Horita H; Ostriker AC; Weiser-Evans MC; Nemenoff RA; Furgeson SB
Mol Pharmacol; 2014 Nov; 86(5):570-9. PubMed ID: 25169989
[TBL] [Abstract][Full Text] [Related]
19. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.
Dummer R; Beyer M; Hymes K; Epping MT; Bernards R; Steinhoff M; Sterry W; Kerl H; Heath K; Ahern JD; Hardwick JS; Garcia-Vargas J; Baumann K; Rizvi S; Frankel SR; Whittaker SJ; Assaf C
Leuk Lymphoma; 2012 Aug; 53(8):1501-8. PubMed ID: 22239668
[TBL] [Abstract][Full Text] [Related]
20. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
Duvic M; Hymes K; Heald P; Breneman D; Martin AG; Myskowski P; Crowley C; Yocum RC;
J Clin Oncol; 2001 May; 19(9):2456-71. PubMed ID: 11331325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
